Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 18;9(5):2559-2566.
doi: 10.1039/c8ra09102a.

Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy

Ting Tang  1   2 , Xiao Sun  3 , Xuedong Xu  4 , Yifeng Bian  1 , Xiaojie Ma  1 , Ning Chen  1
Affiliations

Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy

Ting Tang et al. RSC Adv. .

Erratum in

Abstract

The development of hollow ferrogadolinium nanonetworks has not been reported for nanomedicine application until now. In this study, we developed a hollow and porous ferrogadolinium nanonetwork structure using the one-pot solvothermal method. This nanoparticle could be simultaneously used as a T 1 and T 2 dual-modal magnetic resonance imaging (MRI) contrast agent. In addition, the hollow lumen and abundant pores of the nanonetworks maximized the loading capacity and conferred the nanoplatforms for suitable anticancer drug loading capacity. Using these nanonetworks, MRI and anticancer experiments were conducted in vitro and satisfactory dual-modal MRI and cancer chemotherapy results were obtained. Therefore, the nanonetworks with dual-modal MRI and drug loading abilities effectively complement the ferrogadolinium composites' library and hold great promise in nanomedicine for simultaneous cancer diagnosis and chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1. Schematic of (a) the synthesis for ferrogadolinium nanonetworks and (b) their applications in dual-modal MRI guided cancer chemotherapy.
Fig. 1
Fig. 1. (a) Low magnification and (b) high magnification TEM images of HPFN. Inset: HPFN (0.5 mg mL−1) dispersed in water and DMEM medium. Hydrodynamic size distribution of HPFN. (c) XRD pattern, and (d) N2 adsorption/desorption isotherms of HPFN.
Fig. 2
Fig. 2. (a) Full XPS spectra and N 1s peaks of (b) HPFN, and (c) HPFNC. (d) FT-IR spectrum of HPFN.
Fig. 3
Fig. 3. M − H and M–T curves of HPFN.
Fig. 4
Fig. 4. (a) CLSM images of HeLa cells treated with HPFN-FITC for different indicated times. For each panel, the images from left to right show cell nuclei stained by NucRed Live 647 ReadyProbes Reagent (red), FITC fluorescence in cells (green), bright field, and a merged image of the three left-most images, respectively. All images had the same scale bar of 20 µm.
Fig. 5
Fig. 5. (a) T1 and (b) T2 relaxivity and MR images of HPFN at different concentrations.
Fig. 6
Fig. 6. Biocompatibility of HeLa cells treated with HPFN with increasing concentrations.
Fig. 7
Fig. 7. Viability of HeLa cells treated with free cisplatin and HPFN-cisplatin with increasing cisplatin concentrations for (a) 24 h and 48 h (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mi P. Kokuryo D. Cabral H. Wu H. L. Terada Y. Saga T. Aoki I. Nishiyama N. Kataoka K. Nat. Nanotechnol. 2016;11:724–730. doi: 10.1038/nnano.2016.72. - DOI - PubMed
    1. Smith B. R. Gambhir S. S. Chem. Rev. 2017;117:901–986. doi: 10.1021/acs.chemrev.6b00073. - DOI - PubMed
    1. Sun C. Lee J. S. Zhang M. Q. Adv. Drug Delivery Rev. 2008;60:1252–1265. doi: 10.1016/j.addr.2008.03.018. - DOI - PMC - PubMed
    1. Chen Y. Ai K. Liu J. H. Ren X. Y. Jiang C. H. Lu L. H. Biomaterials. 2016;77:198–206. doi: 10.1016/j.biomaterials.2015.11.010. - DOI - PubMed
    1. Liu J. N. Bu W. B. Shi J. L. Chem. Rev. 2017;117:6160–6224. doi: 10.1021/acs.chemrev.6b00525. - DOI - PubMed